Given that thalassemia is characterized by ineffective erythropoiesis, MEG3 may modulate the p53 signaling pathway to affect the growth and differentiation of erythroid precursor cells, potentially alleviating or exacerbating anemia symptoms in thalassemia patients. Here, TP53 is linked to thalassemia.